Published On: Thu, Mar 17th, 2016

Voyager Therapeutics, Inc. (NASDAQ:VYGR) To Release Earnings

Analysts await Voyager Therapeutics, Inc. (NASDAQ:VYGR) to report earnings on Mar, 17 for the fiscal quarter ending Dec 2015.

They expect $-0.5 EPS, down 100% or $0.5 from last year’s $n/a per share.

At the moment 4 analysts are watching Voyager Therapeutics, Inc. (NASDAQ:VYGR), 1 rate it “Buy”, 2 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 3 analysts have a mean sales target of 2.73 million. For the quarter ending Jun-16, 3 analysts have a mean sales target of 2.73 million whilst for the year ending Dec-16, 4 analysts have a mean target of 14.38 million.

In terms of earnings per share, 3 analysts have a -0.34 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 3 analysts have a -0.36 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -1.28 EPS.

The biggest institutional shareholders in Voyager Therapeutics, Inc. include Third Rock Ventures, LLC which owns 11 million shares in the company valued at $242.24 million. Fidelity Management and Research Company is the second biggest holder with 4 million shares currently valued at 98.30 million whilst Sanofi has 2 million shares valued at 54.27 million.

Total shares held by institutions as of the most recent company filings are 11,336,307 with a reported 20,248 bought and 2,471 sold. These holdings make up 42.38% of the company’s outstanding shares.

Currently insiders hold 1,007,644 shares in the business which makes up 3.77% of shares. The biggest holder currently is Dr. Steven M. Paul, M.D. who owns 862,351 shares (3.22% of those outstanding), whilst Mr. James A. Geraghty holds 70,588 (0.26% of shares outstanding) and Mr. J. Jeffrey Goater holds 64,705 (0.24% of shares outstanding).

The stock increased 4.24% or $0.42 during the last trading session, hitting $15.00. Voyager Therapeutics, Inc. (NASDAQ:VYGR) has risen 100% over the past 6 months and is uptrending.

Receive News & Ratings Via Email

Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: